Advanced Generation Folate Therapy-EnLyte-Patented To Treat High Homocysteine, a Condition Associated with PTSD, Announces JayMac Pharmaceuticals, LLC
| PR Web |
(PRWEB)
PTSD (Post Traumatic Stress Disorder) among military men and women is prevalent, with over 10,000 new cases diagnosed each year, some requiring hospitalization. A link between PTSD and high homocysteine – an amino acid – has been validated in many studies. Many things can contribute to high homocysteine, including extreme stress, as would be expected in PTSD, and genetic issues such as the MTHFR polymorphism. A critical combination of B vitamins and co-factors is needed to keep homocysteine in a healthy range, and when elevated, it can lead to cardiovascular disease, stroke, dementia, and a host of other health problems.
One study published by Levine, et al. in Depression and Anxiety found "the duration of PTSD was found to predict serum homocysteine levels. Our results suggest that elevated levels of homocysteine in male patients with PTSD may be related to pathophysiological aspects associated with the chronicity of this disorder." Another study published by Jendricko, et al. in Progress in NeuroPsychopharmacology & Biological Psychiatry found homocysteine levels significantly higher in men with PTSD than in those without.
Antidepresssants and cognitive therapy are the most common ways to treat this disorder. Adding a homocysteine-lowering agent to this regimen would help improve symptoms and overall health long term. There is only one patented drug containing all of the necessary ingredients to lower homocysteine – EnLyte with Delta Folate. This is a new, natural, advanced generation folate therapy containing all natural, unique, and reduced folates and co-factors, as well as other minerals for overall brain health. It may be used alone or added to an SSRI/SNRI. With both the depression and hyperhomocysteinemia indications, this new drug has huge potential to assist in the military arena:
• Treat PTSD Symptoms and Lower Homocysteine: It would reduce homocysteine levels and would improve clinical drug outcomes when added to an SSRI/SNRI
• Provide a safe, effective, and natural option to treat depression without side effects
• Pregnancy category A
•
• DMLSS coverage
•
To learn more, visit http://www.EnlyteRx.Com.
Read the full story at http://www.prweb.com/releases/2014/07/prweb12044149.htm
| Copyright: | (c) 2014 PRWEB.COM Newswire |
| Wordcount: | 380 |


Doing right by ‘Lady Justice’: Restoration planned for statue, dome
Advisor News
- Succession planning: Building the future of your practice
- From loss to security: Supporting widowed clients with life insurance
- Plan now for lower Social Security benefits later
- The conversation almost no advisor is having yet
- Why advisors should offer retirement-longevity planning
More Advisor NewsAnnuity News
- Empower Annuity Insurance Company of America Trademark Application for “EMPOWER WHAT’S NEXT” Filed: Empower Annuity Insurance Company of America
- Industry pushes back on linking ‘financial strength’ to annuity illustrations
- Sammons Enterprises & Sammons Financial Group Respond to Reports
- The Manhattan Life Insurance Company Acquires Union Security Life Insurance Company of New York
- Cayman Islands premier to meet with U.S. reinsurance regulators
More Annuity NewsHealth/Employee Benefits News
Life Insurance News
- Benchmark International Successfully Facilitated the Transaction Between National Group Marketing Trust and New Era Life Insurance Companies
- Why the bond market is flexing its muscles, and why everyone needs to care
- An Application for the Trademark “LIVE TODAY, SECURE TOMORROW.” Has Been Filed by Security Mutual Life Insurance Company of New York: Security Mutual Life Insurance Company of New York
- Modern Woodmen board selects Shea Doyle as next president and CEO
- New Influenza Study Results from University of Auckland Described (Risk Management In Deadly Times: the Us Life Insurance Industry In the 1918-9 Influenza Pandemic): Influenza
More Life Insurance News